Question 1

What is the AOD-9604 peptide?

Accepted Answer

AOD-9604 is a fragment, not a whole molecule. A 2026 sports medicine review spells the name out as AOD-9604 (anti-obesity drug 9604), which is what the initials stand for. A 2015 analytical paper gives the structure. AOD9604 is a peptide consisting of the C-terminal fragment of human growth hormone from amino acids 177-191 with an additional tyrosine residue at the N-terminus of the peptide. A 2026 endocrinology review writes the same thing a different way, calling it the growth hormone (GH) fragment - AOD9604 (hGH 176-191), so a reader will meet two different numberings for one compound. What that fragment was selected for is narrow. A 2006 pipeline review describes a human growth hormone fragment (AOD-9604) that increases adipose tissue breakdown in the models it covers. Adipose tissue is body fat, and the whole design idea was to retain the fat-releasing portion of growth hormone and discard the remainder.

Question 2

What is AOD-9604 used for?

Accepted Answer

It was built for one purpose and is now discussed in a different field, which is most of the story. The original purpose was obesity. A 2004 development note states that Metabolic is developing AOD-9604 for the potential treatment of obesity. A 2006 cardiovascular review lists it among drugs that improve adipose tissue function or fatty acid metabolism, and places those in clinical trials. A 2007 Polish review of anti-obesity compounds files it under others, as a human growth hormone fragment (AOD9604), alongside a gut lipase inhibitor. A 2012 obesity review lists AOD9604 among recent patents rather than among approved options. Where it turns up now is sports medicine. A 2026 review covers it among prominent approved and unapproved peptides marketed direct to patients, and a 2026 endocrinology review places it among performance-enhancing drugs modulating the growth hormone axis. The compound did not change. The literature around it did.

Question 3

Does AOD-9604 actually work?

Accepted Answer

In rodents, by the numbers in the papers, yes. In people, no study among the research behind this page has published a result either way. The clearest animal finding is from 2000, in obese Zucker rats. Daily oral treatment of these rats for 19 days reduced over 50% of the body weight gain of the animals in comparison with the control. The adipose tissues of the AOD9604-treated animals were found to have an increase in lipolytic activity, which is the rate at which stored fat is released. A 2001 study in obese mice found the same direction. Both hGH and AOD significantly reduced body weight gain in obese mice, and this was associated with increased fat oxidation and increased plasma glycerol levels, glycerol being what shows up in blood when fat is broken down. A 2026 review states the general position for compounds in this group. Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce. Consistent rodent fat loss and an unmeasured human effect are different questions, and only the first has an answer.

Question 4

Has AOD-9604 been tested in people?

Accepted Answer

Yes, and no result from those tests appears in the published literature, which is an odd combination worth setting out carefully. The trials are documented as having started. A 2004 development note records that by February 2002, phase IIa trials were underway. A phase IIa trial is a small early test of whether a compound does anything at all in people. A 2006 cardiovascular review repeats that compounds like this one are in clinical trials. AOD-9604 also appears twice in pipeline indexes. Gateways to Clinical Trials, a guide to the most recent clinical trials in current literature and congresses, lists it in its 2003 issue and again in 2005. Those are listings of activity, not reports of outcomes. A 2026 endocrinology review describes the general problem, stratifying peptides into evidence tiers from regulatory-grade randomized trial data to a complete absence of human studies. A trial that started and a trial that reported are different things, and for this compound a reader only has the first.

Question 5

What happened to the AOD-9604 trials?

Accepted Answer

Development stopped, which is a finding in its own right, and not the same thing as a regulatory withdrawal. A 2006 review of the obesity pipeline is the last point at which AOD-9604 is treated as a live candidate, and even there it had not gone far. Of the compounds that review covered, only rimonabant has got as far as completing phase III clinical trials. AOD-9604 was not among them, and no phase III result for it has been published since. By 2014 the surrounding literature had relocated to a different discipline entirely. A doping-control review from that year summarizes work on new drug entities, discontinued therapeutics, and 'tailored' compounds classified as doping agents, and AOD-9604 sits in that survey. The same year, Belgian authorities seized unknown pharmaceutical preparations and published a case report on AOD9604. A 2015 paper notes that it was recently identified in confiscated vials in the USA. Read carefully what that does and does not establish, because no source among the research behind this page gives a reason for the discontinuation, and nothing on record reports a harm finding that caused it. A compound can leave development because a trial disappointed, because the financing disappeared, or because a company changed direction, and the available record does not distinguish between those possibilities. A stop is a fact about a development programme rather than a verdict on the molecule.

Question 6

How quickly does AOD-9604 work?

Accepted Answer

No study among the research behind this page has measured how fast anything happens in a person given AOD-9604. What exists is a set of rodent schedules, and they divide into two kinds. The chronic experiments ran for two to three weeks. Obese and lean mice were treated with hGH, AOD or saline for 14 days using mini-osmotic pumps, which deliver a steady amount rather than a single shot. A 2001 study used 14 days of repeated dosing in obese mice, and the 2000 rat work ran daily oral dosing for 19 days. One result is faster than that. In an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in the beta(3)-AR knock-out mice, meaning a measurable metabolic shift after a single administration. So the animal record holds a same-day metabolic change and a two-to-three-week weight change. Neither is a timeline for a person, because the measurements were taken from animals bred for obesity research rather than from anyone who could report back. If the question is how much rather than how fast, the AOD-9604 dosage page holds every figure the animal work produced, per kilogram and by route.

Question 7

Does AOD-9604 make you tired?

Accepted Answer

No study among the research behind this page has measured fatigue, sleep or energy in a person given AOD-9604. No account of how it feels appears in these sources, because the research we cite holds no human result at all. What was measured is the machinery underneath. A 2001 mouse study recorded body weight, caloric intake, resting energy expenditure, fat oxidation, glucose oxidation, and plasma glucose, insulin and glycerol before and after treatment. Resting energy expenditure is calories burned at rest, read from a sealed chamber rather than from how the animal behaved. A companion study reported AOD9604 increasing energy expenditure and fat oxidation in mice. The nearest thing to a symptom list belongs to the wider group of peptides, not to this one. A 2026 review reports that adverse effects span endocrine and metabolic upsets, fluid retention, muscle and joint pain, and reactions at the injection site. A reading taken from a mouse in a box and a person's own account of their energy are different questions. The second has not been asked.

Question 8

Is AOD-9604 a growth hormone compound?

Accepted Answer

Two current reviews answer this differently, and the mouse data sides with one of them. A 2026 orthopaedic review puts it in the hormone camp, grouping growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 as compounds that activate IGF-1 signaling and satellite cell repair. A secretagogue is something that makes a gland release its own hormone. A 2026 endocrinology review keeps it separate, listing the growth hormone releasing hormone analogues and the secretagogues in their own groups, and AOD9604 on its own as a fragment. The 2001 mouse experiment is the one that tested it. AOD9604 does not compete for the hGH receptor and nor does it induce cell proliferation, unlike hGH. The authors concluded that fragments of hGH can act in a manner novel to traditional hGH-stimulated pathways. A compound that does not bind the growth hormone receptor is not acting as growth hormone, whatever a classification table says. No study among the research behind this page has measured a hormone level in a person given it.

Question 9

Does AOD-9604 affect blood sugar?

Accepted Answer

The whole selling point of this compound is a blood-sugar claim, and every measurement behind it came from a rodent. A 2015 paper states the claim in one line. AOD9604 is reported to mimic the lipolytic properties of growth hormone without the diabetogenic side effects, meaning fat release without the rise in blood sugar that growth hormone can cause. Two animal experiments sit underneath it. In obese Zucker rats, chronic treatment with AOD9604 showed no adverse effect on insulin sensitivity of the animals, as demonstrated with euglycemic clamp techniques, which is the standard laboratory method for measuring how well insulin works. In obese mice, unlike hGH, AOD9604 did not induce hyperglycaemia or reduce insulin secretion. Read what that covers. Two rodent experiments, over 14 and 19 days, in animals bred for obesity research, by groups testing a hypothesis they had already published. A 2026 review lists dysglycaemia, meaning disordered blood sugar, among the effects reported across this whole group of peptides. A clamp study tells a reader about insulin in a rat rather than about blood sugar in a person, and no human glucose measurement after AOD-9604 has been published.

Question 10

Does AOD-9604 do anything besides fat loss?

Accepted Answer

One experiment says yes, in a joint, in rabbits. A 2015 study used a knee osteoarthritis model. Mature New Zealand white rabbits (n=32) were randomly administered 2 mg collagenase type II twice in each knee joint, which is how the cartilage damage was created. The animals then received weekly injections of saline, hyaluronic acid, AOD9604, or AOD9604 combined with hyaluronic acid. The result favoured the combination. Intra-articular AOD9604 injections using ultrasound guidance enhanced cartilage regeneration in these rabbits, and combined AOD9604 and HA injections were more effective than HA or AOD9604 injections alone in the collagenase-induced knee OA rabbit model. Weigh that properly. It is one study, in 32 rabbits, with the compound placed directly into the damaged joint rather than injected under the skin, and nobody in these sources has repeated it. A cartilage effect at the site of injection and a whole-body fat effect are different claims, and the second is the one this compound was built for.

Question 11

Is AOD-9604 legal, and is it banned in sport?

Accepted Answer

It has no approval and it is banned in competition, and those are two separate statements. On approval, a 2026 endocrinology review is direct about the whole group, writing of the absence of regulatory approval for physique- or performance-related indications. No regulator has cleared AOD-9604 for anything. On sport, a 2015 analytical paper is equally direct. AOD9604 may be used as a performance enhancing drug and is banned by the World Anti-doping Agency (WADA). That paper exists because testing laboratories needed a method: a solid-phase extraction method was validated in urine with a limit of detection of 50 pg/mL. Six potential metabolites of the peptide were identified after incubation of AOD9604 in serum and urine, and one of those breakdown products proved more stable than the parent, widening the window in which a test can find it. A 2014 review of doping detection lists AOD-9604 among the peptide compounds laboratories were being asked to screen for. A ban is a statement about competition rules rather than about what the compound does.

Question 12

Is AOD-9604 safe?

Accepted Answer

No human safety result for AOD-9604 has been published, so there is nothing to weigh against the animal work. The 2000 rat paper ends on a hope rather than a finding, suggesting the analogue may have the potential to be developed into an orally usable and safe therapeutic agent for obesity. Read the tense. That was a proposal written from 19 days of rat data in 2000, and the human trials that would have tested it never reported. A 2026 sports medicine review states the current position for unapproved peptides as a group: rigorous human safety data are scarce, and there is potential for serious harm to patients. A 2026 endocrinology review adds that uncertainty surrounds product composition, dose, and stacking practices in unregulated supply chains. So what a reader has is a 19-day rat study with no adverse effect on insulin sensitivity, a 14-day mouse study, and nothing from a person. Organ-specific questions, interactions, daily use and what the seizure reports found are taken one at a time at the AOD-9604 safety page.

Question 13

How does AOD-9604 work?

Accepted Answer

The proposed route runs through fat cells rather than through the growth hormone receptor, and the mouse work that tested it came back complicated. A 2001 investigation examined beta3-adrenergic receptors, the principal fat-releasing receptors on an individual adipose cell. Weight loss in treated animals correlated with increases in the level of expression of beta(3)-AR RNA, the major lipolytic receptor found in fat cells. Both hGH and AOD9604 were capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice. The same investigators subsequently eliminated the receptor altogether. Long-term treatment with hGH and AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. But the conclusion is not the obvious one: the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta(3)-AR. So the receptor appears necessary for the complete effect without being the direct molecular target, and the compound simultaneously increases how much of it an adipose cell manufactures. That is a mechanism assembled entirely from mouse experiments, and no individual step within it has been measured in a person.

AOD-9604